Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMDINC4)

• Drug Name: Thiothixene Drug Info
• Synonyms: Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
• Therapeutic Class: Antipsychotic Agents
• Cross-matching ID:
  PubChem CID: 941651
  ChEBI ID: CHEMBL1201
  CAS Number: CAS 3313-26-6
  TTD Drug ID: D0E0LQ
  INTEDE Drug ID: DR1584
  ACDINA Drug ID: D00680

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.76	0.00e+0	19/20 (95%)	MSMO1;SQLE;DHCR24;...
Lysosome	2.20	0.00e+0	115/128 (89.84%)	NEU1;NPC2;ACP5;...
Terpenoid backbone biosynthesis	2.20	0.00e+0	18/22 (81.82%)	HMGCS1;IDI1;FDPS;...
Phagosome	2.12	0.00e+0	118/152 (77.63%)	TLR4;TUBA1A;ATP6V1G1;...
Rheumatoid arthritis	2.10	0.00e+0	78/93 (83.87%)	CXCL2;TLR4;CXCL1;...
Ferroptosis	2.10	0.00e+0	36/41 (87.8%)	GPX4;SAT1;HMOX1;...
Epithelial cell signaling in Helicobacter pylori infect...	2.07	0.00e+0	62/70 (88.57%)	CXCL2;CXCL1;LYN;...
mTOR signaling pathway	1.98	3.44e-3	114/154 (74.03%)	LPIN1;RRAGD;ATP6V1G1;...
Salivary secretion	1.97	3.06e-3	76/93 (81.72%)	MUC5B;CST3;ATP2B1;...
Synthesis and degradation of ketone bodies	1.96	2.75e-3	9/10 (90%)	HMGCS1;ACAT2
Vibrio cholerae infection	1.92	7.51e-3	44/50 (88%)	ATP6V1G1;ATP6V0D1;KDELR3;...
Synaptic vesicle cycle	1.90	6.89e-3	63/78 (80.77%)	STX3;ATP6V1G1;ATP6V0D1;...
Osteoclast differentiation	1.87	8.48e-3	117/127 (92.13%)	JUND;SQSTM1;ACP5;...
Autophagy	1.86	8.86e-3	113/169 (66.86%)	SQSTM1;RRAGD;IRS2;...
IL-17 signaling pathway	1.83	1.29e-2	84/94 (89.36%)	CXCL2;JUND;S100A8;...
Sulfur metabolism	1.82	1.21e-2	9/10 (90%)	PAPSS2;ETHE1;TST;...
Cholesterol metabolism	1.79	1.78e-2	44/50 (88%)	NPC2;LDLR;LIPG;...
PPAR signaling pathway	1.79	1.84e-2	66/74 (89.19%)	HMGCS1;SCD;FADS2;...
Legionellosis	1.77	2.17e-2	51/57 (89.47%)	CXCL2;TLR4;CXCL1;...
Other glycan degradation	1.76	2.41e-2	13/18 (72.22%)	NEU1;FUCA1;HEXB;...
Kaposi sarcoma-associated herpesvirus infection	1.76	2.30e-2	172/193 (89.12%)	CXCL2;CXCL1;LYN;...
Pentose phosphate pathway	1.76	2.25e-2	25/30 (83.33%)	G6PD;PGD;ALDOC;...
Biosynthesis of unsaturated fatty acids	1.75	2.16e-2	21/27 (77.78%)	SCD;FADS1;FADS2;...
Staphylococcus aureus infection	1.75	2.07e-2	72/95 (75.79%)	CFB;KRT19;KRT23;...
Tuberculosis	1.74	2.20e-2	159/180 (88.33%)	TLR4;BAX;CD74;...
Glutathione metabolism	1.74	2.17e-2	43/57 (75.44%)	G6PD;GPX4;PGD;...
Butanoate metabolism	1.70	3.06e-2	23/28 (82.14%)	HMGCS1;ACAT2
Mucin type O-glycan biosynthesis	1.69	3.20e-2	20/36 (55.56%)	ST6GALNAC2;GALNT1;GALNT3;...
Fatty acid biosynthesis	1.68	3.29e-2	16/18 (88.89%)	FASN;ACSL1;ACACA;...
GnRH secretion	1.67	3.23e-2	60/64 (93.75%)	SPP1;MAP2K2;GABBR1;...
Parkinson disease	-1.60	4.70e-2	176/249 (70.68%)	CALML4;SDHB;NDUFA2;...
Mismatch repair	-1.63	3.46e-2	22/23 (95.65%)	RFC3;MSH6;MLH3;...
RNA degradation	-1.63	3.85e-2	53/79 (67.09%)	C1D;EXOSC7;DCPS;...
Aminoacyl-tRNA biosynthesis	-1.65	3.79e-2	15/66 (22.73%)	WARS2;LARS2;QRSL1;...
Caffeine metabolism	-1.65	3.86e-2	5/6 (83.33%)	NAT1;CYP2A6;NAT2
Proteasome	-1.85	3.16e-3	44/46 (95.65%)	PSMA7;PSMA3;PSMB2;...
DNA replication	-1.89	3.79e-3	34/36 (94.44%)	RFC3;POLA1;DNA2;...
Ribosome	-2.03	0.00e+0	113/158 (71.52%)	RPL18;RPLP1;RPS24;...
Spliceosome	-2.10	0.00e+0	101/150 (67.33%)	CTNNBL1;DDX5;PRPF3;...
RNA transport	-2.18	0.00e+0	128/186 (68.82%)	FUS;NUP37;EIF1AX;...
Ribosome biogenesis in eukaryotes	-2.36	0.00e+0	52/108 (48.15%)	RBM28;NOL6;POP4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼